Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Nimenrix Co-administered with Routine Vaccines in Infants
NCT01340898Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2012
- Primary completion
- Aug 2014
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of meningococcal group A, C, W135 and Y conjugate vaccine in meningococcal infection (3 arms), sponsored by GSK. Primary endpoint: Serum Bactericidal Assay Using Rabbit Complement (rSBA) Antibody Titers at Month 5. Started Jan 2012; status: completed.
02
Drugs
meningococcal group A, C, W135 and Y conjugate vaccine
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT01340898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01340898.